[General Corporate·M&A]

• Advised on the acquisition of shares in Osstem Implant through a public tender offer by MBK Partners and UCK Partners

• Advised on the business transfer of LG Chem’s diagnostics division

• Advised on the acquisition of a pharmaceutical company specializing in the development of antibody-drug conjugates (ADCs)

• Advised on the asset transfer of over-the-counter (OTC) pharmaceutical products

• Advised Huons Meditech on the acquisition of the lithotripter business unit from M.I.Tech

• Advised a multinational pharmaceutical company on the establishment of its Korean subsidiary

[Healthcare]

• Advised on regulatory compliance under the Pharmaceutical Affairs Act, Medical Devices Act, Medical Service Act, Improper Solicitation and Graft Act, Monopoly Regulation and Fair-Trade Act, and the Fair Competition Code

• Represented clients in investigations and criminal proceedings concerning violations of the Pharmaceutical Affairs Act and Medical Devices Act

• Advised on reassessment procedures for reimbursement eligibility of pharmaceutical products

• Provided legal advice on labeling, representation, and advertising of pharmaceuticals, cosmetics, and food products

• Represented a pharmaceutical company in administrative litigation challenging administrative sanctions

• Represented a client in litigation seeking suspension of price reduction measures imposed on originator drugs following the launch of generics during a patent dispute